Metoclopramide

Adult population Metoclopramide hydrochloride is indicated in adults for: • Prevention of post operative nausea and vomiting (PONV) • Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting - Prevention of radiotherapy induced nausea and vomiting (RINV).

Paediatric population Metoclopramide hydrochloride is indicated in children (aged 1 – 18 years) for: Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option - Treatment of established post operative nausea and vomiting (PONV) as a second line option.

INDICATIONS AND USAGE

The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration. Symptomatic Gastroesophageal Reflux Metoclopramide Oral Solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.

The principal effect of metoclopramide is on symptoms of post-prandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day.

Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg 4 times daily. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.

5 mg/kg BODY WEIGHT.

As an Adjunct in the Management of Delayed Gastric Emptying Adults:

When parenteral administration is required, 2 mL (10 mg) IM or IV (slowly) 2 or 3 times daily as needed.

For the Prophylaxis of Cisplatin-Induced Vomiting Adults:

For the patients treated with cisplatin in doses up to and including 100 mg/m2, Metoclopramide Hydrochloride Injection may be administered by infusion after dilution (See Intravenous Infusion) in single doses of 1 mg/kg of body weight.

For patients treated with cisplatin doses greater than 100 mg/m2, the single recommended dose may be increased to 2 mg/kg body weight administered by infusion. Infuse slowly over a 15-minute period and repeat the dose every 2 hours for two doses, then every 3 hours for three doses.